Skip to main content
. 2020 Jan 14;11(3):594–602. doi: 10.1111/1759-7714.13302

Figure 3.

Figure 3

Changes in chest CT findings in some patients who accepted osimertinib after abivertinib treatment. (a) Patient No.9 achieved a PR from abivertinib treatment, with PFS of 170 days. Subsequent treatment with osimertinib achieved another PR, and PFS following osimertinib treatment was as long as one year (his disease was still under control). (b) Patient No.7 progressed after one month of abivertinib treatment; the target lesion in her lung remained stable while the nontarget lesion increased, then a PR was achieved after osimertinib treatment and PFS was longer than 10 months. (c) Patient No.1 developed interstitial lung disease after abivertinib treatment, with a response of SD following abivertinib; after the switch to osimertinib, a PR was achieved without the recurrence of ILD, and PFS following osimertinib treatment was 12 months.